RxDoctor Payments Data

Terry Lawson, APRN

Nurse Practitioner · Whitley City, KYNPI 1851613228

Payments from drug & device makers

$1,560in general payments, 2019–2025

Across 106 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$628
  • AstraZeneca$352
  • GSK$168
  • Lilly USA, LLC$90
  • Abiomed$64
  • Boehringer Ingelheim$51
  • plus $207 from 11 others

What the payments were for

  • Food & beverage$1,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,560 in reported general payments places this provider in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$1,161
Medicare patients
59
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide237$238,261
MounjaroTirzepatide99$103,835
JanuviaSitagliptin Phosphate79$67,416
EliquisApixaban67$63,216
FarxigaDapagliflozin Propanediol83$54,785
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$29,891
XareltoRivaroxaban29$27,637
JanumetSitagliptin Phos/Metformin Hcl28$22,090
TrulicityDulaglutide21$21,991
JardianceEmpagliflozin31$21,014
LinzessLinaclotide24$13,122
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$12,305
Tresiba Flextouch U-100Insulin Degludec26$12,094
Praluent PenAlirocumab22$10,793
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$9,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$628$238,261237 claims
Lilly USA, LLCMounjaro, Trulicity$90$125,826120 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$352$79,069136 claims
GSKTrelegy Ellipta$168$29,89142 claims
Boehringer IngelheimJardiance$51$21,01431 claims
AbbVieLinzess, Synthroid$14$14,52058 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Whitley City

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →